Aziz Mottiwala - Nov 2, 2021 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Commercial Officer
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Nov 2, 2021
Transactions value $
-$160,690
Form type
4
Date filed
11/4/2021, 07:03 PM
Previous filing
Sep 14, 2021
Next filing
Nov 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Sale -$146K -5.46K -9.38% $26.75 52.7K Nov 2, 2021 Direct F1, F2
transaction TARS Common Stock Sale -$14.7K -542 -1.03% $27.07 52.2K Nov 2, 2021 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021.
F2 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.020 to $27.015. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $27.020 to $27.730. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.